NeoDynamics Nomination Committee proposes Matt Colpoys as a new member of the Board. Matt Colpoys is an American with broad experience from the healthcare sector where he worked with orphan drugs and precision medicine. Today, Matt leverages his experience as a consultant for biotech and medical device companies, specializing in business development and commercialization.
“With Matt, we bring in strong expertise from the US, which is a key market for NeoDynamics. He has contributed to a number of successful launches and deals in the sector. I look forward to welcoming him to the board,” says NeoDynamics chairman Ingrid Salén.
“I am very excited about the prospects of NeoDynamics pulse technology and the profound impact their NeoNavia system will have on women’s health. I look forward to working with the company’s Board of Directors and management to maximize shareholder value via successful commercialization of our technology across the globe,” says Matt Colpoys.
Matt Colpoys is active at Galileo Consulting, where he is president and has previously held commercial positions at, among others, Insmed, Genentech and Pharmacia.
The Nomination Committee proposes the re-election of the Board members Carina Bolin, Claes Pettersson, Ingrid Salén, Jie Bao and Xiao-Jun Xu, and that Ingrid Salén is re-elected as Chair.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail firstname.lastname@example.org
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden.
NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.